NCT00073515已完成2 期
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 115
- 试验地点
- 1
研究概览
简要总结
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic DermatitisAtopic Dermatitis EczemaNCT03235024AOBiome LLC122
已完成
2 期
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.Atopic DermatitisNCT03725722LEO Pharma251
进行中（未招募）
1 期
Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczemaChronic hand eczemaMedDRA version: 20.0Level: LLTClassification code 10066695Term: Chronic hand dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: SOCClassification code 10040785Term: Skin and subcutaneous tissue disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-000900-40-DKEO Pharma A/S250
已完成
2 期
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate RosaceaRosaceaNCT03590366AOBiome LLC140
已完成
2 期
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisPlaque PsoriasisNCT03837743Durect25